Evidence map›Paper›PMID 36419137›Full record

ArticleMolecular neurodegeneration2022

Opposing effects of apoE2 and apoE4 on microglial activation and lipid metabolism in response to demyelination.

Na Wang, Minghui Wang, Suren Jeevaratnam, Cassandra Rosenberg, Tadafumi C Ikezu, Francis Shue, Sydney V Doss, Alla Alnobani, Yuka A Martens, Melissa Wren and 4 more

Open access · goldAbstract read
In one paragraph

Article in Molecular neurodegeneration, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 69 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. APOE-Targeted Therapeutics for Alzheimer's Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Review
  18. Review
  19. Amyloid-Related Imaging Abnormality (ARIA) Beyond the APOE-ε4 Allele.Chronic diseases and translational medicine · 2025
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Na WangDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Minghui WangDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Suren JeevaratnamDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Cassandra RosenbergDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Tadafumi C IkezuDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Francis ShueDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Sydney V DossDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Alla AlnobaniDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Yuka A MartensDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Melissa WrenDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Yan W AsmannDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, 32224, USA.
Bin ZhangDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Guojun BuDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA. Guojun.Bu@MolecularNeurodegeneration.org.
Chia-Chen LiuDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA. liu.chiachen@mayo.edu.ORCID 0000-0001-7203-3926
Mayo Clinic in Florida · USIcahn School of Medicine at Mount Sinai · USJacksonville College · US

Funding

Project 4 (Genetic modifiers for APOE-associated Alzheimer's disease pathogenesis)U19AG069701 · NIA · MAYO CLINIC JACKSONVILLE · PI Na Zhao · 2021 to 2026
$42.0M
ApoE isoform-specific therapy for Alzheimer diseaseRF1AG046205 · NIA · MAYO CLINIC JACKSONVILLE · PI ZHAO, NA · 2019 to 2019
$3.1M
ApoE pathway in cerebrovascular Aβ clearance in Alzheimer’s diseaseR37AG027924 · NIA · MAYO CLINIC JACKSONVILLE · PI BU, GUOJUN · 2017 to 2020
$2.4M
NIA NIH HHS R37 AG027924NIA NIH HHS RF1 AG046205NIA NIH HHS U19 AG069701
6 · The paper itself

Abstract

backgroundAbnormal lipid accumulation has been recognized as a key element of immune dysregulation in microglia whose dysfunction contributes to neurodegenerative diseases. Microglia play essential roles in the clearance of lipid-rich cellular debris upon myelin damage or demyelination, a common pathogenic event in neuronal disorders. Apolipoprotein E (apoE) plays a pivotal role in brain lipid homeostasis; however, the apoE isoform-dependent mechanisms regulating microglial response upon demyelination remain unclear.

methodsTo determine how apoE isoforms impact microglial response to myelin damage, 2-month-old apoE2-, apoE3-, and apoE4-targeted replacement (TR) mice were fed with normal diet (CTL) or 0.2% cuprizone (CPZ) diet for four weeks to induce demyelination in the brain. To examine the effects on subsequent remyelination, the cuprizone diet was switched back to regular chow for an additional two weeks. After treatment, brains were collected and subjected to immunohistochemical and biochemical analyses to assess the myelination status, microglial responses, and their capacity for myelin debris clearance. Bulk RNA sequencing was performed on the corpus callosum (CC) to address the molecular mechanisms underpinning apoE-mediated microglial activation upon demyelination.

resultsWe demonstrate dramatic isoform-dependent differences in the activation and function of microglia upon cuprizone-induced demyelination. ApoE2 microglia were hyperactive and more efficient in clearing lipid-rich myelin debris, whereas apoE4 microglia displayed a less activated phenotype with reduced clearance efficiency, compared with apoE3 microglia. Transcriptomic profiling revealed that key molecules known to modulate microglial functions had differential expression patterns in an apoE isoform-dependent manner. Importantly, apoE4 microglia had excessive buildup of lipid droplets, consistent with an impairment in lipid metabolism, whereas apoE2 microglia displayed a superior ability to metabolize myelin enriched lipids. Further, apoE2-TR mice had a greater extent of remyelination; whereas remyelination was compromised in apoE4-TR mice.

conclusionsOur findings provide critical mechanistic insights into how apoE isoforms differentially regulate microglial function and the maintenance of myelin dynamics, which may inform novel therapeutic avenues for targeting microglial dysfunctions in neurodegenerative diseases.

Indexed as

Apolipoprotein E4Demyelinating DiseasesAnimalsApolipoprotein E2Apolipoprotein E3Apolipoproteins ECuprizoneLipid MetabolismMiceMicrogliaApolipoprotein E2Apolipoprotein E3Apolipoprotein E4Apolipoproteins ECuprizoneapoE isoformsDemyelinationLipid dropletsMicrogliaRemyelination

Identifiers

PMID36419137
PMCPMC9682675
OpenAlexW4309838288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.